Other Events ·
Radiopharm Theranostics announced on August 26, 2026, that it has dosed the first patient in the second cohort of its…
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics announced on August 26, 2026, that it has dosed the first patient in the second cohort of its Phase 1/2a First-In-Human clinical trial for RV-01 (177Lu-Betabart). The Safety and Monitoring Committee recommended advancing to the 70 mCi dose level. RV-01 is a radiopharmaceutical therapeutic targeting B7-H3, developed through a joint venture with MD Anderson Cancer Center. The trial aims to enroll 61 participants across various solid tumors including prostate, colorectal, and lung cancers. Radiopharm Theranostics operates in the biotechnology industry, specifically developing clinical-stage radiotherapeutics for oncology.